TIGAR and neoplasm: We intragastically administrated CB-839, a GLS inhibitor, to Tigar+/+ or Tigar-/- mice with 4-NQO induced primary ESCC for 18 days and observed that Tigar+/+ mice had significantly fewer tumors, smaller tumor size, and a significant recovery from body weight loss as compared with the control mice; however, these effects were not observed in Tigar-/- mice (Figures 4A-C; Figure S5A).